A randomized phase II trial comparing chemoimmunotherapy with or without bevacizumab in previously untreated patients with chronic lymphocytic leukemia
Authors:
Open Access
- 16 November 2016
- journal article
- research article
- Published by Impact Journals, LLC in Oncotarget
- Vol. 7 (48) , 78269-78280
Abstract
Bevacizumab is a monoclonal antibody targeting vascular endothelial growth factor (VEGF) with in vitro pro-apoptotic and antiangiogenic effects on chronic lymphocytic leukemia (CLL) cells. As monotherapy in patients with CLL, it has no clinical activity. Here we report the results of an open-label, randomized phase II trial comparing the combination of pentostatin, cyclophosphamide and rituximab (PCR) either without or with bevacizumab (PCR-B) in previously untreated CLL patients. A total of 65 evaluable patients were enrolled, 32 receiving PCR and 33 PCR-B. A higher rate of grade 3-4 cardiovascular toxicity was observed with PCR-B (33% vs. 3%, p < 0.003). Patients treated with PCR-B had a trend for a higher complete remission (CR) rate (54.5% vs 31.3%; p = 0.08), longer progression-free survival (PFS)(p = 0.06) and treatment-free survival (TFS)(p = 0.09). No differences in PFS and TFS by IGHV mutational status were observed with the addition of bevacizumab. A significant post-treatment increase in VEGF levels was observed in the PCR-B arm (29.77 to 57.05 pg/mL); in the PCR-B arm, lower baseline CCL-3 levels were significantly associated with achievement of CR (p = 0.01). In conclusion, the addition of bevacizumab to chemoimmunotherapy in CLL is generally well-tolerated and appears to prolong PFS and TFS.Keywords
This publication has 47 references indexed in Scilit:
- Microenvironment interactions and B-cell receptor signaling in Chronic Lymphocytic Leukemia: Implications for disease pathogenesis and treatmentBiochimica et Biophysica Acta (BBA) - Molecular Cell Research, 2016
- Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trialBlood, 2016
- Targeted Therapies Improve Outlook for Chronic Lymphocytic LeukemiaJNCI: Journal of the National Cancer Institute, 2015
- Mutations driving CLL and their evolution in progression and relapseNature, 2015
- Cancer therapy and cardiovascular risk: focus on bevacizumabCancer Management and Research, 2015
- Comprehensive assessment of chemokine expression profiles by flow cytometryJournal of Clinical Investigation, 2010
- Multiple circulating proangiogenic factors induced by sunitinib malate are tumor-independent and correlate with antitumor efficacyProceedings of the National Academy of Sciences, 2007
- Community-Based Phase II Trial of Pentostatin, Cyclophosphamide, and Rituximab (PCR) Biochemotherapy in Chronic Lymphocytic Leukemia and Small Lymphocytic LymphomaCancer Biotherapy and Radiopharmaceuticals, 2007
- VEGF receptor phosphorylation status and apoptosis is modulated by a green tea component, epigallocatechin-3-gallate (EGCG), in B-cell chronic lymphocytic leukemiaBlood, 2004
- Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal CancerNew England Journal of Medicine, 2004